253 related articles for article (PubMed ID: 36420264)
1. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma.
Li S; Chen Z; Liu M; Li L; Cai W; Lian ZX; Guan H; Xu B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214937
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter.
Yu H; Huang X; Liu X; Jin H; Zhang G; Zhang Q; Yu J
Endocrine; 2013 Aug; 44(1):172-81. PubMed ID: 23264145
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
5. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract][Full Text] [Related]
6. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
[TBL] [Abstract][Full Text] [Related]
7. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
8. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.
Liu Y; Yun X; Gao M; Yu Y; Li X
Clin Transl Oncol; 2015 Apr; 17(4):274-80. PubMed ID: 25387566
[TBL] [Abstract][Full Text] [Related]
9. Location of CD39
Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
[TBL] [Abstract][Full Text] [Related]
10. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
[TBL] [Abstract][Full Text] [Related]
11. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
13. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer.
French JD; Kotnis GR; Said S; Raeburn CD; McIntyre RC; Klopper JP; Haugen BR
J Clin Endocrinol Metab; 2012 Jun; 97(6):E934-43. PubMed ID: 22466343
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
16. Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma.
Dong DN; Fan PW; Feng YN; Liu GH; Peng YC; Dong T; Wang RZ; Yu JM
Chin Med J (Engl); 2021 Aug; 134(17):2066-2072. PubMed ID: 34435978
[TBL] [Abstract][Full Text] [Related]
17. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
19. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer.
Gorchs L; Fernández-Moro C; Asplund E; Oosthoek M; Solders M; Ghorbani P; Sparrelid E; Rangelova E; Löhr MJ; Kaipe H
Cancer Res Commun; 2024 Feb; 4(2):460-474. PubMed ID: 38335302
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]